Drug-induced mitochondrial dysfunction in cardiac and skeletal muscle injury

Expert Opinion on Drug Safety

Volumn 7, Issue 2, 2008, Pages 129-146

  Sardão, Vilma A ^a   Pereira, Sandro L ^a   Oliveira, Paulo J ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Drug induced toxicity; Heart; Mitochondria; Skeletal muscle

Indexed keywords

ALCOHOL; ALPHA TOCOPHEROL; ANTHRACYCLINE; ATORVASTATIN; BUPIVACAINE; CALCIUM; CARVEDILOL; CERIVASTATIN; CLOFIBRATE; COCAINE; DOXORUBICIN; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIDOCAINE; LOCAL ANESTHETIC AGENT; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; THIAZOLIDINE DERIVATIVE; UBIDECARENONE; UBIQUINONE; ZIDOVUDINE;

ALCOHOL ABUSE; ANTIOXIDANT ACTIVITY; BRADYCARDIA; CALCIUM HOMEOSTASIS; CARDIOMYOPATHY; CARDIOTOXICITY; COCAINE DEPENDENCE; CONGESTIVE HEART FAILURE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG INHIBITION; DRUG MECHANISM; FLUID THERAPY; HEART ARREST; HEART ARRHYTHMIA; HEART MITOCHONDRION; HUMAN; HYPOLIPEMIA; HYPOTENSION; LIVER TOXICITY; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL PERMEABILITY; MUSCLE DISEASE; MYOGLOBINURIA; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

HUMANS; MITOCHONDRIA, HEART; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; MYOCARDIUM; PHARMACEUTICAL PREPARATIONS;

EID: 41349119625     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.2.129     Document Type: Review

References (163)

1. McMillin-Wood J, Wolkowicz PE, Chu A, Tate CA, Goldstein MA, Entman ML. Calcium uptake by two preparations of mitochondria from heart. Biochim Biophys Acta 1980;591(2):251-65
2. Palmer JW, Tandler B, Hoppel CL. Heterogeneous response of subsarcolemmal heart mitochondria to calcium. Am J Physiol 1986;250(5 Pt 2):H741-8
3. Hoppeler H. Exercise-induced ultrastructural changes in skeletal muscle. Int J Sports Med 1986;7(4):187-204
4. Palmer JW, Tandler B, Hoppel CL. Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. J Biol Chem 1977;252(23):8731-9
5. Berry RM. ATP synthesis: the world's smallest wind-up toy. Curr Biol 2005;15(10):R385-7
6. Blachly-Dyson E, Forte M. VDAC channels. IUBMB Life 2001;52(3-5):113-8
7. Forner F, Foster LJ, Campanaro S, Valle G, Mann M. Quantitative proteomic comparison of rat mitochondria from muscle, heart, and liver. Mol Cell Proteomics 2006;5(4):608-19
8. Menin L, Panchichkina M, Keriel C, et al. Macrocompartmentation of total creatine in cardiomyocytes revisited. Mol Cell Biochem 2001;220(1-2):149-59
9. Joubert F, Hoerter JA, Mazet JL. Modeling the energy transfer pathways. creatine kinase activities and heterogeneous distribution of ADP in the perfused heart. Mol Biol Rep 2002;29(1-2):177-82
10. Garlid KD, Paucek P, Yarov-Yarovoy V, Sun X, Schindler PA. The mitochondrial KATP channel as a receptor for potassium channel openers. J Biol Chem 1996;271(15):8796-9
11. Hu H, Sato T, Seharaseyon J, et al. Pharmacological and histochemical distinctions between molecularly defined sarcolemmal KATP channels and native cardiac mitochondrial KATP channels. Mol Pharmacol 1999;55(6):1000-5
12. Liu Y, Sato T, O'Rourke B, Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 1998;97(24):2463-9
13. Moses MA, Addison PD, Neligan PC, et al. Mitochondrial KATP channels in hindlimb remote ischemic preconditioning of skeletal muscle against infarction. Am J Physiol Heart Circ Physiol 2005;288(2):H559-67
14. Drose S, Brandt U, Hanley PJ. K+-independent actions of diazoxide question the role of inner membrane KATP channels in mitochondrial cytoprotective signaling. J Biol Chem 2006;281(33):23733-9
15. Facundo HT, Carreira RS, de Paula JG, et al. Ischemic preconditioning requires increases in reactive oxygen release independent of mitochondrial K+ channel activity. Free Radic Biol Med 2006;40(3):469-79
16. Das M, Parker JE, Halestrap AP. Matrix volume measurements challenge the existence of diazoxide/glibencamide-sensitive KATP channels in rat mitochondria. J Physiol 2003;547(Pt 3):893-902
17. Franzini-Armstrong C. ER-mitochondria communication. How privileged? Physiology (Bethesda) 2007;22:261-8
18. Pacher P, Csordas P, Schneider T, Hajnoczky G. Quantification of calcium signal transmission from sarco-endoplasmic reticulum to the mitochondria. J Physiol 2000;529(Pt 3):553-64
19. McCormack JG, Denton RM. The role of Ca2+ in the regulation of intramitochondrial energy production in heart. Biomed Biochim Acta 1987;46(8-9):S487-92
20. Hopper RK, Carroll S, Aponte AM, et al. Mitochondrial matrix phosphoproteome: effect of extra mitochondrial calcium. Biochemistry 2006;45(8):2524-36
21. Harris DA. Regulation of the mitochondrial ATP synthase in rat heart. Biochem Soc Trans 1993;21(Pt 3)(3):778-81
22. Bell CJ, Bright NA, Rutter GA, Griffiths EJ. ATP regulation in adult rat cardiomyocytes: time-resolved decoding of rapid mitochondrial calcium spiking imaged with targeted photoproteins. J Biol Chem 2006;281(38):28058-67
23. Sedova M, Dedkova EN, Blatter LA. Integration of rapid cytosolic Ca2+ signals by mitochondria in cat ventricular myocytes. Am J Physiol Cell Physiol 2006;291(5):C840-50
24. Gunter TE, Pfeiffer DR. Mechanisms by which mitochondria transport calcium. Am J Physiol 1990;258(5 Pt 1):C755-86
25. Barja G. Mitochondrial oxygen radical generation and leak: sites of production in states 4 and 3, organ specificity, and relation to aging and longevity. J Bioenerg Biomembr 1999;31(4):347-66
26. Nohl H, Gille L, Schonheit K, Liu Y. Conditions allowing redox-cycling ubisemiquinone in mitochondria to establish a direct redox couple with molecular oxygen. Free Radic Biol Med 1996;20(2):207-13
27. Zhang Y, Marcillat O, Giulivi C, Ernster L, Davies KJ. The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J Biol Chem 1990;265(27):16330-6
28. Winterbourn CC, Metodiewa D. Reactivity of biologically important thiol compounds with superoxide and hydrogen peroxide. Free Radic Biol Med 1999;27(3-4):322-8
29. Hoch FL. Cardiolipins and biomembrane function. Biochim Biophys Acta 1992;1113(1):71-133
30. Tsutsui H, Ide T, Kinugawa S. Mitochondrial oxidative stress, DNA damage, and heart failure. Antioxid Redox Signal 2006;8(9-10):1737-44
31. Bernardi P. Mitochondrial transport of cations: channels, exchangers, and permeability transition. Physiol Rev 1999;79(4):1127-55
32. Vercesi AE, Kowaltowski AJ, Grijalba MT, Meinicke AR, Castilho RF. The role of reactive oxygen species in mitochondrial permeability transition. Biosci Rep 1997;17(1):43-52
33. Bernardi P. Modulation of the mitochondrial cyclosporin A-sensitive permeability transition pore by the proton electrochemical gradient. Evidence that the pore can be opened by membrane depolarization. J Biol Chem 1992;267(13):8834-9
34. Halestrap AP, Woodfield KY, Connern CP. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J Biol Chem 1997;272(6):3346-54
35. Ruck A, Dolder M, Wallimann T, Brdiczka D. Reconstituted adenine nucleotide translocase forms a channel for small molecules comparable to the mitochondrial permeability transition pore. FEBS Lett 1998;426(1):97-101
36. Connern CP, Halestrap AP. Recruitment of mitochondrial cyclophilin to the mitochondrial inner membrane under conditions of oxidative stress that enhance the opening of a calcium-sensitive non-specific channel. Biochem J 1994;302(Pt 2):321-4
37. Szabo I, De Pinto V, Zoratti M. The mitochondrial permeability transition pore may comprise VDAC molecules. II. The electrophysiological properties of VDAC are compatible with those of the mitochondrial megachannel. FEBS Lett 1993;330(2):206-10
38. Beutner G, Ruck A, Riede B, Brdiczka D. Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases. Biochim Biophys Acta 1998;1368(1):7-18
39. Brustovetsky N, Klingenberg M. Mitochondrial ADP/ATP carrier can be reversibly converted into a large channel by Ca2+. Biochemistry 1996;35(26):8483-8
40. Forte M, Bernardi P. Genetic dissection of the permeability transition pore. J Bioenerg Biomembr 2005;37(3):121-8
41. Krauskopf A, Eriksson O, Craigen WJ, Forte MA, Bernardi P. Properties of the permeability transition in VDAC1 (-/-) mitochondria. Biochim Biophys Acta 2006;1757(5-6):590-5
42. Kokoszka JE, Waymire KG, Levy SE, et al. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 2004;427 (6973):461-5
43. Fontaine E, Eriksson O, Ichas F, Bernardi P. Regulation of the permeability transition pore in skeletal muscle mitochondria. Modulation By electron flow through the respiratory chain complex i. J Biol Chem 1998;273(20):12662-8
44. Ichas F, Mazat JP. From calcium signaling to cell death: two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state. Biochim Biophys Acta 1998;1366(1-2):33-50
45. Broekemeier KM, Dempsey ME, Pfeiffer DR. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J Biol Chem 1989;264(14):7826-30
46. Kowaltowski AJ, Netto LE, Vercesi AE. The thiol-specific antioxidant enzyme prevents mitochondrial permeability transition. Evidence for the participation of reactive oxygen species in this mechanism. J Biol Chem 1998;273(21):12766-9
47. Petronilli V, Costantini P, Scorrano L, Colonna R, Passamonti S, Bernardi P. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. Increase of the gating potential by oxidants and its reversal by reducing agents. J Biol Chem 1994;269(24):16638-42
48. Csukly K, Ascah A, Matas J, Gardiner PF, Fontaine E, Burelle Y. Muscle denervation promotes opening of the permeability transition pore and increases the expression of cyclophilin D. J Physiol 2006;574(Pt 1):319-27
49. S PM, Alway SE. Mitochondria-associated apoptotic signalling in denervated rat skeletal muscle. J Physiol 2005;565(Pt 1):309-23
50. Adhihetty PJ, Ljubicic V, Menzies KJ, Hood DA. Differential susceptibility of subsarcolemmal and intermyofibrillar mitochondria to apoptotic stimuli. Am J Physiol Cell Physiol 2005;289(4):C994-1001
51. Yang JC, Cortopassi GA. Induction of the mitochondrial permeability transition causes release of the apoptogenic factor cytochrome c. Free Radic Biol Med 1998;24(4):624-31
52. Scarlett JL, Murphy MP. Release of apoptogenic proteins from the mitochondrial intermembrane space during the mitochondrial permeability transition. FEBS Lett 1997;418(3):282-6
53. Zamzami N, Marchetti P, Castedo M, et al. Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett 1996;384(1):53-7
54. Marzo I, Brenner C, Zamzami N, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998;281(5385):2027-31
55. Bauer MK, Schubert A, Rocks O, Grimm S. Adenine nucleotide translocase-1, a component of the permeability transition pore, can dominantly induce apoptosis, J Cell Biol 1999;147(7):1493-1502
56. Arcamone F, Cassinelli G, Fantini G, et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Reprinted from Biotechnology and Bioengineering, Vol. XI, Issue 6, Pages 1101-1110 (1969). Biotechnol Bioeng 2000;67(6):704-13
57. Gasparini M. Anthracycline cardiotoxicity. Pediatr Hematol Oncol 1994;11(3):237-40
58. Wallace KB. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 2003;93(3):105-15
59. Doroshow JH, Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res 1983;43(10):4543-51
60. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339(13):900-5
61. Goormaghtigh E, Pollakis G, Ruysschaert JM. Mitochondrial membrane modifications induced by adriamycin-mediated electron transport. Biochem Pharmacol 1983;32(5):889-93
62. Goormaghtigh E, Ruysschaert JM. Evidence of a covalent linkage in the adriamycin-cardiolipin complex induced by adriamycin-mediated electron transport. Res Commun Chem Pathol Pharmacol 1983;42(1):149-52
63. Mimnaugh EG, Trush MA, Gram TE. Enhancement of rat heart microsomal lipid peroxidation following doxorubicin treatment in vivo. Cancer Treat Rep 1983;67(7-8):731-3
64. Palmeira CM. Serrano J, Kuehl DW, Wallace KB. Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim Biophys Acta 1997;1321(2):101-6
65. Solem LE, Henry TR, Wallace KB. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol Appl Pharmacol 1994;129(2):214-22
66. Oliveira PJ, Wallace KB. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubidn-treated rats-relevance for mitochondrial dysfunction. Toxicology 2006;220(2-3):160-8
67. Wallace KB. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 2007;7(2):101-7
68. Solem LE, Wallace KB. Selective activation of the sodium-independent, cyclosporin A-sensitive calcium pore of cardiac mitochondria by doxorubicin. Toxicol Appl Pharmacol 1993;121(1):50-7
69. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 2001;61(2):771-7
70. Bianchi C, Bagnato A, Paggi MG, Floridi A. Effect of adriamycin on electron transport in rat heart, liver, and tumor mitochondria. Exp Mol Pathol 1987;46(1):123-35
71. Muhammed H, Ramasarma T, Kurup CK. Inhibition of mitochondrial oxidative phosphorylation by adriamycin. Biochim Biophys Acta 1983;722(1):43-50
72. Ferrero ME, Ferrero E, Gaja G, Bernelli-Zazzera A. Adriamycin: energy metabolism and mitochondrial oxidations in the heart of treated rabbits. Biochem Pharmacol 1976;25(2):125-30
73. Gosalvez M, Blanco M, Hunter J, Miko M, Chance B. Effects of anticancer agents on the respiration of isolated mitochondria and tumor cells. Eur J Cancer 1974;10(9):567-74
74. Clementi ME, Giardina B, Di Stasio E, Mordente A, Misiti F. Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res 2003;23(3B):2445-50
75. Oliveira PJ, Bjork JA, Santos MS, et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 2004;200(2):159-68
76. Porta EA, Joun NS, Matsumura L, Nakasone B, Sablan H. Acute adriamycin cardiotoxicity in rats. Res Commun Chem Pathol Pharmacol 1983;41(1):125-37
77. Nithipongvanitch R, Ittarat W, Velez JM, Zhao R, St Clair DK, Oberley TD. Evidence for p53 as guardian of the cardiomyocyte mitochondrial genome following acute adriamycin treatment. J Histochem Cytochem 2007;55(6):629-39
78. Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 2002;185(3):218-27
79. Berthiaume JM, Oliveira PJ, Fariss MW, Wallace KB. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. Cardiovasc Toxicol 2005;5(3):257-67
80. Oliveira PJ, Santos MS, Wallace KB. Doxorubicin-induced thiol-dependent alteration of cardiac mitochondrial permeability transition and respiration. Biochemistry (Mosc) 2006;71(2):194-9
81. Ellis CN, Ellis MB, Blakemore WS. Effect of adriamycin on heart mitochondrial DNA. Biochem J 1987;245(1):309-12
82. Adachi K, Fujiura Y, Mayumi F, et al. A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun 1993;195(2):945-51
83. Ogihara M, Tanno M, Izumiyama N, Nakamura H, Taguchi T. Increase in DNA polymerase gamma in the hearts of adriamycin-administered rats. Exp Mol Pathol 2002;73(3):234-41
84. Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA, Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol 2005;207(4):436-44
85. Zhou S, Heller LJ, Wallace KB. Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicol Appl Pharmacol 2001;175(1):60-7
86. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000;60(7):1789-92
87. Lewis W, Kohler JJ, Hosseini SH, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 2006;20(5):675-84
88. Lund KC, Wallace KB. Direct, DNA pol-gamma-independent effects of nucleoside reverse transcriptase inhibitors on mitochondrial bioenergetics. Cardiovasc Toxicol 2004;4(3):217-28
89. Lewis W, Simpson JF, Meyer RR. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 1994;74(2):344-8
90. Lund KC, Wallace KB. Direct effects of nucleoside reverse transcriptase inhibitors on rat cardiac mitochondrial bioenergetics. Mitochondrion 2004;4(2-3):193-202
91. Lynx MD, Bentley AT, McKee EE. 3′-Azido-3′-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: a possible mechanism of AZT hepatotoxicity. Biochem Pharmacol 2006;71(9):1342-8
92. Lynx MD, McKee EE. 3′-Azido-3′-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol 2006;72(2):239-43
93. de la Asuncion JG, Del Olmo ML, Gomez-Cambronero LG, Sastre J, Pallardo FV, Vina J. AZT induces oxidative damage to cardiac mitochondria: protective effect of vitamins C and E. Life Sci 2004;76(1):47-56
94. Szabados E, Fischer GM, Toth K, et al. Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. Free Radic Biol Med 1999;26(3-4):309-17
95. Valenti D, Barile M, Passarella S. AZT inhibition of the ADP/ATP antiport in isolated rat heart mitochondria. Int J Mol Med 2000;6(1):93-6
96. Lund KC, Wallace KB. Adenosine 3′,5′-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors. Toxicol Appl Pharmacol 2008;226(1):94-106
97. Hebert VY, Crenshaw BL, Romanoff RL, Ekshyyan VP, Dugas TR. Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. Cardiovasc Toxicol 2004;4(2):117-31
98. Cazzalini O, Lazze MC, Iamele L, et al. Early effects of AZT on mitochondrial functions in the absence of mitochondrial DNA depletion in rat myotubes. Biochem Pharmacol 2001;62(7):893-902
99. Lewis W, Papoian T, Gonzalez B, et al. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. Lab Invest 1991;65(2):228-36
100. Urbano-Marquez A, Fernandez-Sola J. Effects of alcohol on skeletal and cardiac muscle. Muscle Nerve 2004;30(6):689-707
101. Rakotovao A, Berthonneche C, Guiraud A, et al. Ethanol, wine, and experimental cardioprotection in ischemia/reperfusion: role of the prooxidant/antioxidant balance. Antioxid Redox Signal 2004;6(2):431-8
102. Sato M, Maulik N, Das DK. Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants. Ann NY Acad Sci 2002;957:122-35
103. Vendemiale G, Grattagliano I, Altomare E, et al. Mitochondrial oxidative damage and myocardial fibrosis in rats chronically intoxicated with moderate doses of ethanol. Toxicol Lett 2001;123(2-3):209-16
104. Mansouri A, Demeilliers C, Amsellem S, Pessayre D, Fromenty B. Acute ethanol administration oxidatively damages and depletes mitochondrial DNA in mouse liver, brain, heart, and skeletal muscles: protective effects of antioxidants. J Pharmacol Exp Ther 2001;298(2):737-43
105. Marin-Garcia J, Ananthakrishnan R, Goldenthal MJ. Heart mitochondria response to alcohol is different than brain and liver. Alcohol Clin Exp Res 1995;19(6):1463-6
106. Hajnoczky G, Buzas CJ, Pacher P, Hoek JB, Rubin E, Alcohol and mitochondria in cardiac apoptosis: mechanisms and visualization. Alcohol Clin Exp Res 2005;29(5):693-701
107. Bakeeva LE, Skulachev VP, Sudarikova YV, Tsyplenkova VG. Mitochondria enter the nucleus (one further problem in chronic alcoholism). Biochemistry (Mosc) 2001;66(12):1335-41
108. Om A. Cardiovascular complications of cocaine. Am J Med Sci 1992;303(5):333-9
109. Devi BG, Chan AW. Effect of cocaine on cardiac biochemical functions. J Cardiovasc Pharmacol 1999;33(1):1-6
110. Xiao Y, He J, Gilbert RD, Zhang L. Cocaine induces apoptosis in fetal myocardial cells through a mitochondria-dependent pathway. J Pharmacol Exp Ther 2000;292(1):8-14
111. Zhang L, Xiao Y, He J. Cocaine and apoptosis in myocardial cells. Anat Rec 1999;257(6):208-16
112. Yuan C, Acosta D Jr. Effect of cocaine on mitochondrial electron transport chain evaluated in primary cultures of neonatal rat myocardial cells and in isolated mitochondrial preparations. Drug Chem Toxicol 2000;23(2):339-48
113. Lattanzio FA Jr, Tiangco D, Osgood C, Beebe S, Kerry J, Hargrave BY. Cocaine increases intracellular calcium and reactive oxygen species, depolarizes mitochondria, and activates genes associated with heart failure and remodeling. Cardiovasc Toxicol 2005;5(4):377-90
114. Tiangco DA, Lattanzio FA Jr, Osgood CJ, Beebe SJ, Kerry JA, Hargrave BY. 3,4-Methylenedioxymethamphetamine activates nuclear factor-kappaB, increases intracellular calcium, and modulates gene transcription in rat heart cells. Cardiovasc Toxicol 2005;5(3):301-10
115. Campbell WW. Statin myopathy: the iceberg or its tip? Muscle Nerve 2006;34(4):387-90
116. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294(19):2437-45
117. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000;22(6):441-57
118. Gambelli S, Dotti MT, Malandrini A, et al. Mitochondrial alterations in muscle biopsies of patients on statin therapy. J Submicrosc Cytol Pathol 2004;36(1):85-9
119. Goldfarb S. Regulation of hepatic cholesterogenesis. Int Rev Physiol 1980;21:317-56
120. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289(13):1681-90
121. Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 2001;24(5):258-72
122. Brookes PS, Yoon Y, Robotham JL, Anders MW, Sheu SS. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 2004;287(4):C817-33
123. Sirvent P, Mercier J, Vassort G, Lacampagne A. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun 2005;329(3):1067-75
124. Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion 2007;7(Suppl):S168-74
125. Bentinger M, Brismar K, Dallner G. The antioxidant role of coenzyme Q. Mitochondrion 2007;7(Suppl):S41-50
126. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996;42(3):333-7
127. Chan A, Reichmann H, Kogel A, Beck A, Gold R. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol 1998;245(10):681-5
128. Kaufmann P, Torok M, Zahno A, Waldhauser KM, Brecht K, Krahenbuhl S. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 2006;63(19-20):2415-25
129. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007;1771(8):1065-81
130. Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 2001;56:239-63
131. Shimkets RA, Lowe DG, Tai JT, et al. Gene expression analysis by transcript profiling coupled to a gene database query. Nat Biotechnol 1999;17(8):798-803
132. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47(4):507-14
133. Feinstein DL, Spagnolo A, Akar C, et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 2005;70(2):177-88
134. Scatena R, Martorana GE, Bottoni P, Giardina B. Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs). IUBMB Life 2004;56(8):477-82
135. Youssef J, Badr M. Extraperoxisomal targets of peroxisome proliferators: mitochondrial, microsomal, and cytosolic effects. Implications for health and disease. Crit Rev Toxicol 1998;28(1):1-33
136. Brunmair B, Staniek K, Gras F, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 2004;53(4):1052-9
137. Patel C, Wyne KL, McGuire DK. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab Vasc Dis Res 2005;2(2):61-6
138. Smith MT. Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 2003;16(6):679-87
139. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 2002;128(1-3):159-68
140. Li N, Ragheb K, Lawler G, et al. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 2003;278(10):8516-25
141. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-71
142. Amir R, Argoff CE, Bennett GJ, et al. The role of sodium channels in chronic inflammatory and neuropathic pain, J Pain 2006;7(5 Suppl 3):S1-29
143. Dullenkopf A, Borgeat A. Local anesthetics. Differences and similarities in the "-cains". Anaesthesist 2003;52(4):329-40
144. Jaffe AS. The use of antiarrhythmics in advanced cardiac life support. Ann Emerg Med 1993;22(2 Pt 2):307-16
145. Centini F, Fiore C, Riezzo I, Rossi G, Fineschi V. Suicide due to oral ingestion of lidocaine: a case report and review of the literature. Forensic Sci Int 2007;171(1):57-62
146. Alto LE, Dhalla NS. Effects of some antiarrhythmic agents on dog heart mitochondrial oxidative phosphorylation. Eur J Pharmacol 1979;59(3-4):311-4
147. Chazotte B, Vanderkooi G, Chignell D. Further studies on F 1-ATPase inhibition by local anesthetics. Biochim Biophys Acta 1982;680(3):310-6
148. Dzimiri N, Almotrefi AA. Investigation of class I anti-arrhythmic drug actions on guinea-pig cardiac mitochondrial lactate dehydrogenase activity. Clin Exp Pharmacol Physiol 1993;20(4):201-6
149. Tsutsumi Y, Oshita S, Kawano T, et al. Lidocaine and mexiletine inhibit mitochondrial oxidation in rat ventricular myocytes. Anesthesiology 2001;95(3):766-70
150. Heavner JE. Cardiac toxicity of local anesthetics in the intact isolated heart model: a review. Reg Anesth Pain Med 2002;27(6):545-55
151. Weinberg G. Lipid rescue resuscitation from local anaesthetic cardiac toxicity. Toxicol Rev 2006;25(3):139-45
152. Schonfeld P, Sztark F, Slimani M, Dabadie P, Mazat JP. Is bupivacaine a decoupler, a protonophore or a proton-leak-inducer? FEBS Lett 1992;304(2-3):273-6
153. Sztark F, Ouhabi R, Dabadie P, Mazat JP. Effects of the local anesthetic bupivacaine on mitochondrial energy metabolism: change from uncoupling to decoupling depending on the respiration state. Biochem Mol Biol Int 1997;43(5):997-1003
154. Sztark F, Malgat M, Dabadie P, Mazat JP. Comparison of the effects of bupivacaine and ropivacaine on heart cell mitochondrial bioenergetics. Anesthesiology 1998;88(5):1340-9
155. Zhang S, Yao S, Li Q. Effects of ropivacaine and bupivacaine on rabbit myocardial energetic metabolism and mitochondria oxidation. J Huazhong Univ Sci Technolog Med Sci 2003;23(2):178-9, 83
156. Sztark F, Nouette-Gaulain K, Malgat M, Dabadie P, Mazat JP. Absence of stereospecific effects of bupivacaine isomers on heart mitochondrial bioenergetics. Anesthesiology 2000;93(2):456-62
157. Weinberg GL, Palmer JW, VadeBoncouer TR, Zuechner MB, Edelman G, Hoppel CL. Bupivacaine inhibits acylcarnitine exchange in cardiac mitochondria. Anesthesiology 2000;92(2):523-8
158. Hall-Craggs EC. Early ultrastructural changes in skeletal muscle exposed to the local anaesthetic bupivacaine (Marcaine). Br J Exp Pathol 1980;61(2):139-49
159. Irwin W, Fontaine E, Agnolucci L, et al. Bupivacaine myotoxicity is mediated by mitochondria. J Biol Chem 2002;277(14):12221-7
160. Murray J, Schilling B, Row RH, et al. Small-scale immunopurification of cytochrome c oxidase for a high-throughput multiplexing analysis of enzyme activity and amount. Biotechnol Appl Biochem 2007;48(Pt 4):167-78
161. Will Y, Hynes J, Oguttsov VI, Papkovsky DB. Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes. Nat Protoc 2006;1(6):2563-72
162. Antczak C, Shum D, Escobar S, et al. High-throughput identification of inhibitors of human mitochondrial peptide deformylase. J Biomol Screen 2007;12(4):521-35
163. Dykens JA, Marroquin LD, Will Y. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev Mol Diagn 2007;7(2):161-75